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Table S1. Sources of data for estimate of observational associations with plasma urate concentration. 
 
 
 
Data Source SBP DBP TC TG HDL-C LDL-C Creatinine BMI Glucose 
Liese et al.1999.s1  1005 1005 1005 - 1005 - 1005 1005 - 
Puddu et al. 2001.s2 2469 - - - 2469 - - 2469 2469 
Fang et al. 2000.s3 5926 5926 5926 - - - - 5926 - 
Medalie et al. 1973.s4 6411 6411 6411 6411 - - - 6411 6411 
Moriarity et al. 2000.s5 13504 - - 13504 13504 13504 - 13504 - 
UCLEB consortiums6 5691 5691 5691 5691 5691 5691 5691 5691 5691 
Tomita et al.2000.s7 49413 - 49413 - - - - 49413 - 
 
 
 
 
 
Note: Estimates reported for smoking, age, sex, eGFR and, diabetes were made in UCLEB consortium data 
only.  
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Table S2. Sources of data used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* BRHS and BWHHS; § BRHS, BWHHS and CaPS; Moriarty et al consisted of 4 communities
Association (A with B) Data N individuals N studies 
Observational Association 
Urate – lipid phenotypes 
Leise et al. 
s1
 
Puddu et al.
 s2 
Medalie et al. 
s4 
Moriarty et al. 
s5 
UCLEB 
 s6
 
1 005 
2 469 
6 411 
13 504 
5 691 
1 
1 
1 
1 
2* 
Urate – BMI 
Leise et al. 
s1
 
Puddu et al.
s2 
Medalie et al. 
s4 
Moriarty et al. 
s5 
Fang et al. 
s3
 
Tomita et al.
s7
 
 
UCLEB
s6  
 
1 005 
2 469 
6 411 
13 504 
5 926 
49 413 
5 691 
 
1 
1 
1 
1 
1 
1 
3§ 
Urate – T2D UCLEB
s6
 4394 2* 
Urate – fasting glucose 
Leise et al. 
s1
 
Puddu et al. 
s2 
Moriarty et al. 
s5 
UCLEB
 s6
 
1 005 
2 469 
13 504 
5 691 
1 
1 
1 
3§ 
Urate - BP 
Leise et al. 
s1
 
Puddu et al. 
s2 
Medalie et al. 
s4 
Moriarty et al. 
s5 
Fang et al. 
s3
 
Tomita et al.
s7 
UCLEB
 s6
 
1 005 
2 469 
6 411 
13 504 
5 926 
49 413 
5 691 
1 
1 
1 
1 
1 
1 
3§ 
Urate - CHD 
Wheeler et al.
4 
 
UCLEB
 s6
 
174 326(9 458 cases) 
1 944 (326 cases) 
17 
1 
Genetic Association 
SNP - urate  
Köttgen et al.
s8
 
Kolz et al.
 s9
 
UCLEB
 s6
 
110 347 
27 817 
7 151 
48 
14 
3 
SNP – CHD 
CARDIoGRAM
s10 
and/or  
C4D
s11
 or  
CARDIoGRAM plus C4D
s12
 
with UCLEB
 s6
 
78 856 (19 368 cases) 
30 393 (15 357 cases) 
186 203 (60 785 cases) 
12 395 (2 131 cases) 
37 
14 
48 
7 
SNP – lipid phenotypes 
GLGC
s13 
UCLEB
 s6
 
187 190 
9 431 
64 
4 
SNP – T2D 
DIAGRAM
s14 
UCLEB
 s6
 
69 033 (12 717 cases) 
15 605 (2 643 cases) 
12 
8 
SNP – fasting glucose 
MAGIC
 s15 
UCLEB
 s6
 
46 186 
11 211 
21 
7 
SNP - BP 
ICBP
 s16 
UCLEB
 s6
 
69 590 
20 077 
29 
8 
SNP - BMI GIANT
s17
 127 600 64 
Confounding associations 
TC - CHD 
Liese et al, UCLEB, Fang et al. Tomita et al, 
Medalie et al.
s1,s3,s4,s6,s7 
 
64 446 5 
HDLc - CHD 
Liese et al, UCLEB, Puddu et al., Moriarity et 
al.
s1,s2,s5,s6 
 
22 669 4 
LDLc - CHD UCLEB, Moriarity et al. 
s5, s6
 19 195 2 
TG - CHD Moriarity et al, UCLEB, Medalie et al.
s4,s5, s6
 25 606 3 
BMI - CHD 
Fang et al, Moriarity et al., Puddu et al., Liese et 
al., UCLEB, Tomita et al., Medalie et al.
s1-s7,   
 
84 419 7 
Fasting glucose - CHD Puddu et al., UCLEB, Medalie et al. 
s2,s4,s6 
15 471 3 
SBP - CHD 
Fang et al., Moriarity et al., Puddu et al., Liese et 
al., UCLEB, Tomita et al. Medalie
 
et al.
s1,s4,s6,s7
 
84 419 7 
DPB - CHD 
Liese et al., UCLEB, Fang et al. Tomita et al., 
Medalie et al. 
s1,s3,s4,s6,s7 
 
19 033 4 
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Table S3. SNPs used to construct the genetic instrument for plasma uratea.  
Ind
ex 
SNP CHR BP GENE 
(nearest/GRAIL) 
Allel
e 
Meta-
analysis 
beta 
Meta-
analysis  
SE 
N S Source Data 
1 rs1471633 1 14443509
6 
PDZK1/PDZK1 A 0·0568 0·0050 116404 54 Köttgen
s8
 and UCLEB
s6
 
2 rs1260326 2 27584444 GCKR/GCKR T 0·0693 0·0049 117293 54 Köttgen
s8
 and UCLEB
s6 
3 rs1249874
2 
4 9553150 SLC2A9/SLC2A9 A 0·3600 0·0051 145110 68 Köttgen
s8
, UCLEB
s6
 Kolz
s9
 
4 rs2231142 4 89271347 ABCG2/ABCG2 T 0·1896 0·0077 140915 68 Köttgen
s8
, UCLEB
s6
 and Kolz
s9
 
5 rs675209 6 7047083 RREB1/RREB1 T 0·0556 0·0059 117293 54 Köttgen
s8
 and UCLEB
s6
 
6 rs1165151 6 25929595 SLC17A1/SLC17A3 T -0·0779 0·0042 145201 68 Köttgen
s8
, UCLEB
s6
 and Kolz
s9
 
7 rs1171614 10 61139544 SLC16A9/SLC16A9 T -0·0790 0·0070 110000 49 Köttgen
s8
 
8 rs2078267 11 64090690 SLC22A11/SLC22A1
1 
T -0·0732 0·0058 117293 54 Köttgen
s8
 and UCLEB
s6
 
9 rs478607 11 64234639 NRXN2/SLC22A12 A -0·0264 0·0056 137967 49 Köttgen
s8
 
10 rs3741414 12 56130316 INHBC/INHBE T -0·0649 0·0068 117293 54 Köttgen
s8
 and UCLEB
s6
 
11 rs1126434
1 
1 15341811
7 
TRIM46/PKLR T -0·0500 0·0060 110000 49 Köttgen
s8
  
12 rs1705027
2 
2 12102291
0 
INHBB/INHBB A 0·0350 0·0060 110000 49 Köttgen
s8
 
13 rs6770152 3 53075254 SFMBT1/MUSTN1 T -0·0440 0·0050 110000 49 Köttgen
s8
 
14 rs1763215
9 
5 72467238 TMEM171/TMEM171 C -0·0390 0·0060 110000 49 Köttgen
s8
 
15 rs729761 6 43912549 VEGFA/VEGFA T -0·0470 0·0060 110000 49 Köttgen
s8
  
16 rs1178977 7 72494985 BAZ1B/MLXIPL A 0·0470 0·0070 110000 49 Köttgen
s8
 
17 rs1048030
0 
7 15103693
8 
PRKAG2/PRKAG2 T 0·0350 0·0060 110000 49 Köttgen
s8
 
18 rs2941484 8 76641323 HNF4G/HNF4G T 0·0440 0·0050 110000 49 Köttgen
s8
 
19 rs1082190
5 
10 52316099 A1CF/ASAH2 A 0·0570 0·0070 110000 49 Köttgen
s8
  
20 rs642803 11 65317196 OVOL1/LTBP3 T -0·0360 0·0050 110000 49 Köttgen
s8
 
21 rs653178 12 11049213
9 
ATXN2/PTPN11 T -0·0350 0·0050 110000 49 Köttgen
s8
 
22 rs1394125 15 73946038 UBE2Q2/NRG4 A 0·0430 0·0060 110000 49 Köttgen
s8
 
23 rs6598541 15 97088658 IGF1R/IGF1R A 0·0430 0·0060 110000 49 Köttgen
s8
  
24 rs7193778 16 68121391 NFAT5/NFAT5 T -0·0460 0·0080 110000 49 Köttgen
s8
 
25 rs7188445 16 78292488 MAF/MAF A -0·0320 0·0050 110000 49 Köttgen
s8
 
26 rs7224610 17 50719787 HLF/HLF A -0·0420 0·0050 110000 49 Köttgen
s8
 
27 rs742132 6 25715550 LRRC16A/LRRC16A A 0·0540 0·0092 27923 14 Kolz
s9
 
28 rs2307394 2 14843289
8 
ORC4L/ACVR2A T -0·0290 0·0050 110000 49 Köttgen
s8
  
29 rs1778674
4 
8 23832951 STC1/STC1 A -0·0290 0·0050 110000 49 Köttgen
s8
 
30 rs2079742 17 56820479 BCAS3/C17orf82 T 0·0430 0·0080 110000 49 Köttgen
s8
 
31 rs164009 17 71795264 QRICH2/PRPSAP1 A 0·028 0·005 110000 49 Köttgen
s8
 
 
  
                                                             
a
 Units are SD uric acid per copy of effect allele using a population SD for uric acid of 90·7 μmol/L (=1·5 mg/dl) reported by 
CHARGE. (Yang et al.).
2 
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Table S4. Association of the 31 SNP plasma urate instrument with cardiovascular traits. 
Cardio-vascular 
trait* 
Difference in risk factor per inverse variance 
weighted allele. 
95%CI 
 
HDL-C (mmol/L) -0.0079 -0.0096, -0.0062 
LDL-C (mmol/L) -0.0014 -0.0032, 0.0005 
TC (mmol/L) 0.0003 -0.0015, 0.0021 
TG (mmol/L) 0.0142 0.0125, 0.0158 
SBP (mm Hg) 0.0045 0.0026, 0.0064 
DBP (mm Hg) 0.0054 0.0033, 0.0074 
Fasting glucose 
(mmol/L) 
-0.0010 -0.0026, 0.0006 
BMI (kg/m
2
) -0.0003 -0.0008, 0.0002 
Diabetes (OR) 0.9991 0.992, 1.0064 
* See Table S2 for numbers of individuals and studies 
 
 
 
 
Table S5. Proxy SNPs used in the Instrument. 
 
 
Index Lead SNP Proxy SNP R
2
 
3 rs12498742 rs734553 0.89 
6 rs1165151 rs1183201 1 
9 rs478607 rs505802 0.44 
 
 
 
 
Table S6. Power (two-sided α=0·05) for conventional IV regression of the binary outcomes. 
 
 
 
 
 
 
 
 
  
Outcome 
Proportion 
cases 
Observational 
OR (per SD 
urate) 
R
2
 of 
instrument 
N required for 
80% power 
Actual 
n 
Power at 
actual n 
CHD 0·317  1·07 0·042 183868 198598 0.83 
T2D 0·175 1·32 0·042 13910 84638 1 
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Table S7. Power (α=0·05) for conventional IV regression of the continuous outcomes. 
 
Outcome (units) β
yx
(true),a R2 
N required 
for 80% 
power 
Actual n 
Power at 
actual n 
LDL-C (mmol/L) 0·073 0·042 34882 196621 1 
HDL-C (mmol/L) -0·183 0·042 5394 196621 1 
TC (mmol/L) 0·129 0·042 11044 196621 1 
TG (mmol/L) 0·265 0·042 2475 196621 1 
SBP (mmHg) 0.163 0·042 6847 89667 1 
DBP (mmHg) 0.169 0·042 6357 89667 1 
Fasting Glucose 
(mmol/L) 
-0·039 0·042 122697 57397 0·48 
 
 
 
Table S8. Gene Ontology Enrichment Analysis. 
 
 
Term (GO reference) 
Background 
frequency  
Sample 
frequency  
Bonferroni 
corrected P-
value 
urate metabolic process (GO:0046415)  13 7 3.96E-13 
purine-containing compound metabolic 
process (GO:0072521)  311 8 5.57E-05 
heterocycle metabolic process (GO:0046483)  4328 19 1.84E-03 
cellular aromatic compound metabolic process 
(GO:0006725)  4332 19 1.87E-03 
organic cyclic compound metabolic process 
(GO:1901360)  4571 19 4.51E-03 
cellular nitrogen compound metabolic process 
(GO:0034641)  4598 19 4.97E-03 
nitrogen compound metabolic process 
(GO:0006807)  5014 19 2.01E-02 
                                                             
a
 See Table S2 for sources of data used to estimate the regression coefficient. Units are SD/SD. 
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Table S9. Function and druggability of genes represented in the genetic instrument for plasma urate. 
SNP CHR GENE 
(nearest/G
RAIL) 
Drugs Gene function (from; http://www.genecards.org/) 
rs1471633 1 PDZK1/PDZ
K1 
None PDZK1: This gene encodes a PDZ domain-containing scaffolding 
protein. PDZ domain-containing molecules bind to and mediate the 
subcellular localization of target proteins. The encoded protein 
mediates the localization of cell surface proteins and plays a critical 
role in cholesterol metabolism by regulating the HDL receptor, 
scavenger receptor class B type 1. Single nucleotide polymorphisms 
in this gene may be associated with metabolic syndrome, and 
overexpression of this gene may play a role in drug resistance of 
multiple myeloma. Pseudogenes of this gene are located on the long 
arm of chromosome 1. Alternatively spliced transcript variants 
encoding multiple isoforms have been observed for this gene. 
rs1260326 2 GCKR/GCK
R 
In development. 61 This gene encodes a protein belonging to the GCKR subfamily of 
the SIS (Sugar ISomerase) family of proteins. The gene product is a 
regulatory protein that inhibits glucokinase in liver and pancreatic 
islet cells by binding non-covalently to form an inactive complex with 
the enzyme. This gene is considered a susceptibility gene candidate 
for a form of maturity-onset diabetes of the young (MODY).  
rs12498742 4 SLC2A9/SL
C2A9 
None This gene encodes a member of the SLC2A facilitative glucose 
transporter family. Members of this family play a significant role in 
maintaining glucose homeostasis. The encoded protein may play a 
role in the development and survival of chondrocytes in cartilage 
matrices. Two transcript variants encoding distinct isoforms have 
been identified for this gene.  
rs2231142 4 ABCG2/AB
CG2 
 The membrane-associated protein encoded by this gene is included 
in the superfamily of ATP-binding cassette (ABC) transporters. ABC 
proteins transport various molecules across extra- and intra-cellular 
membranes. ABC genes are divided into seven distinct subfamilies 
(ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is 
a member of the White subfamily. Alternatively referred to as a 
breast cancer resistance protein, this protein functions as a 
xenobiotic transporter which may play a major role in multi-drug 
resistance. It likely serves as a cellular defense mechanism in 
response to mitoxantrone and anthracycline exposure. Significant 
expression of this protein has been observed in the placenta, which 
may suggest a potential role for this molecule in placenta tissue. 
Multiple transcript variants encoding different isoforms have been 
found for this gene.  
rs675209 6 RREB1/RR
EB1 
None RREB1: The protein encoded by this gene is a zinc finger 
transcription factor that binds to RAS-responsive elements (RREs) 
of gene promoters. It has been shown that the calcitonin gene 
promoter contains an RRE and that the encoded protein binds there 
and increases expression of calcitonin, which may be involved in 
Ras/Raf-mediated cell differentiation. Multiple transcript variants 
encoding several different isoforms have been found for this gene.  
LY86: May cooperate with CD180 and TLR4 to mediate the innate 
immune response to bacterial lipopolysaccharide (LPS) and cytokine 
production. Important for efficient CD180 cell surface expression (By 
similarity) 
rs1165151 6 SLC17A1/S
LC17A3 
None SLC17A1 (solute carrier family 17 (organic anion transporter), 
member 1) is a protein-coding gene. Diseases associated with 
SLC17A1 include cardiovascular disease risk factor. GO annotations 
related to this gene include sodium-dependent phosphate 
transmembrane transporter activity and symporter activity. An 
important paralog of this gene is SLC17A7. 
rs1171614 10 SLC16A9/S
LC16A9 
None SLC16A9 (solute carrier family 16, member 9) is a protein-coding 
gene. GO annotations related to this gene include symporter activity. 
An important paralog of this gene is SLC16A4. 
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SNP CHR GENE 
(nearest/G
RAIL) 
Drugs Gene function (from; http://www.genecards.org/) 
rs2078267 11 SLC22A11/
SLC22A11 
Probenecid SLC22A11 (solute carrier family 22 (organic anion/urate transporter), 
member 11) is a protein-coding gene. Diseases associated with 
SLC22A11 include cardiovascular disease risk factor. GO 
annotations related to this gene include inorganic anion exchanger 
activity and sodium-independent organic anion transmembrane 
transporter activity. An important paralog of this gene is SLC22A5. 
rs478607 11 NRXN2/SL
C22A12 
Sulfinpyrazone SLC22A12 (solute carrier family 22 (organic anion/urate 
transporter), member 12) is a protein-coding gene. Diseases 
associated with SLC22A12 include renal hypouricemia 1, and renal 
hypouricemia. GO annotations related to this gene include PDZ 
domain binding and urate transmembrane transporter activity. An 
important paralog of this gene is SLC22A11. 
rs3741414 12 INHBC/INH
BE 
None INHBC (inhibin, beta C) is a protein-coding gene. Diseases 
associated with INHBC include gastric diffuse adenocarcinoma, and 
endometrial adenocarcinoma. GO annotations related to this gene 
include growth factor activity and transforming growth factor beta 
receptor binding. An important paralog of this gene is GDF11. / 
INHBE: (inhibin, beta E) is a protein-coding gene. Diseases 
associated with INHBE include endometrial adenocarcinoma, and 
germ cell tumors. GO annotations related to this gene include 
growth factor activity and hormone activity. An important paralog of 
this gene is GDF11. 
rs11264341 1 TRIM46/PK
LR 
None/compounds 
in development 
TRIM46: Protein coding. Paaralog is  TRIM13 which is associated 
with leukemia.  PKLR: The protein encoded by this gene is a 
pyruvate kinase that catalyzes the transphosphorylation of 
phohsphoenolpyruvate into pyruvate and ATP, which is the rate-
limiting step of glycolysis. Associated with hemolytic anemia.  
rs17050272 2 INHBB/INH
BB 
None INHBB: A protein-coding gene. Diseases associated with INHBB 
include varicocele, and ectopic pregnancy. GO annotations related 
to this gene include growth factor activity and protein 
homodimerization activity. An important paralog of this gene is 
GDF11. 
rs6770152 3 SFMBT1/M
USTN1 
None/None SFMBT1: (Scm-like with four mbt domains 1) is a protein-coding 
gene. Diseases associated with SFMBT1 include normal pressure 
hydrocephalus, and acute poststreptococcal glomerulonephritis. GO 
annotations related to this gene include histone binding and 
transcription corepressor activity. An important paralog of this gene 
is L3MBTL1./MUSTN1: May be involved in the development and 
regeneration of the musculoskeletal system (By similarity) 
rs17632159 5 TMEM171/T
MEM171 
None Transmembrane protein. 
rs729761 6 VEGFA/VE
GFA 
Pegaptanib 
Sodium(Top), 
Ranibizumab(Top), 
Aflibercept(Top), 
Bevacizumab(Can) 
Growth factor active in angiogenesis, vasculogenesis and 
endothelial cell growth. Induces endothelial cell proliferation, 
promotes cell migration, inhibits apoptosis and induces 
permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and 
KDR/VEGFR2 receptors, heparan sulfate and heparin. 
NRP1/Neuropilin-1 binds isoforms     VEGF-165 and VEGF-145. 
Isoform VEGF165B binds to KDR but does not activate downstream 
signaling pathways, does not activate angiogenesis and inhibits 
tumor growth. 
rs1178977 7 BAZ1B/MLX
IPL 
None/None BAZ1B: (bromodomain adjacent to zinc finger domain, 1B) is a 
protein-coding gene. Diseases associated with BAZ1B include 
williams-beuren syndrome, and williams syndrome. GO annotations 
related to this gene include chromatin binding and non-membrane 
spanning protein tyrosine kinase activity. An important paralog of this 
gene is BAZ1A./MLXIPL: This gene encodes a basic helix-loop-helix 
leucine zipper transcription factor of the Myc/Max/Mad superfamily. 
This protein forms a heterodimeric complex and binds and activates, 
in a glucose-dependent manner, carbohydrate response element 
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SNP CHR GENE 
(nearest/G
RAIL) 
Drugs Gene function (from; http://www.genecards.org/) 
(ChoRE) motifs in the promoters of triglyceride synthesis genes. The 
gene is deleted in Williams-Beuren syndrome, a multisystem 
developmental disorder caused by the deletion of contiguous genes 
at chromosome 7q11.23. 
rs10480300 7 PRKAG2/P
RKAG2 
None PRKAG2 (protein kinase, AMP-activated, gamma 2 non-catalytic 
subunit) is a protein-coding gene. Diseases associated with 
PRKAG2 include cardiomyopathy, familial hypertrophic 6, and wolff-
parkinson-white syndrome. GO annotations related to this gene 
include protein kinase binding and cAMP-dependent protein kinase 
regulator activity. An important paralog of this gene is PRKAG1 
rs2941484 8 HNF4G/HN
F4G 
None HNF4G (hepatocyte nuclear factor 4, gamma) is a protein-coding 
gene. GO annotations related to this gene include steroid hormone 
receptor activity and sequence-specific DNA binding transcription 
factor activity. An important paralog of this gene is RXRA. 
rs10821905 10 A1CF/ASA
H2 
None  A1CF: Essential component of the apolipoprotein B mRNA editing 
enzyme complex which is responsible for the postranscriptional 
editing of a CAA codon for Gln to a UAA codon for stop in APOB 
mRNA. Binds to APOB mRNA and is probably responsible for 
docking the catalytic subunit, APOBEC1, to the mRNA to allow it to 
deaminate its target cytosine. The complex also protects the edited 
APOB mRNA from nonsense-mediated decay/ASAH2: Hydrolyzes 
the sphingolipid ceramide into sphingosine and free fatty acid at an 
optimal pH of 6.5-8.5. Acts as a key regulator of sphingolipid 
signaling metabolites by generating sphingosine at the cell surface. 
Acts as a repressor of apoptosis both by reducing C16-ceramide, 
thereby preventing ceramide-induced apoptosis, and generating 
sphingosine, a precursor of the antiapoptotic factor sphingosine 1-
phosphate. Probably involved in the digestion of dietary 
sphingolipids in intestine by acting as a key enzyme for the 
catabolism of dietary sphingolipids and regulating the levels of 
bioactive sphingolipid metabolites in the intestinal tract.  
rs642803 11 OVOL1/LTB
P3 
None OVOL1:  Putative transcription factor. Involved in hair formation and 
spermatogenesis. May function in the differentiation and/or 
maintenance of the urogenital system (By similarity)/LTBP3:     May 
be involved in the assembly, secretion and targeting of TGFB1 to 
sites at which it is stored and/or activated. May play critical roles in 
controlling and directing the activity of TGFB1. May have a structural 
role in the extra cellular matrix (ECM) 
rs653178 12 ATXN2/PTP
N11 
None/Enoxolone ATXN2: Involved in EGFR trafficking, acting as negative regulator of 
endocytic EGFR internalization at the plasma membrane./PTPN11:      
Acts downstream of various receptor and cytoplasmic protein 
tyrosine kinases to participate in the signal transduction from the cell 
surface to the nucleus. Dephosphorylates ROCK2 at Tyr-722 
resulting in stimulatation of its RhoA binding activity. 
rs1394125 15 UBE2Q2/N
RG4 
None UBE2Q2:     Accepts ubiquitin from the E1 complex and catalyzes its 
covalent attachment to other proteins. In vitro catalyzes 'Lys-48'-
linked polyubiquitination/ NRG4: Low affinity ligand for the ERBB4 
tyrosine kinase receptor. Concomitantly recruits ERBB1 and ERBB2 
coreceptors, resulting in ligand-stimulated tyrosine phosphorylation 
and activation of the ERBB receptors. Does not bind to the ERBB1, 
ERBB2 and ERBB3 receptors (By similarity) 
rs6598541 15 IGF1R/IGF1
R 
Mecasermin 
Rinfabate (Igf), 
Mecasermin(Igf) 
IGF1R: IGF1R (insulin-like growth factor 1 receptor) is a protein-
coding gene. Diseases associated with IGF1R include insulin-like 
growth factor 1 resistance to, and insulin-like growth factor i 
deficiency. GO annotations related to this gene include insulin 
receptor binding and identical protein binding. An important paralog 
of this gene is ROR1. 
rs7193778 16 NFAT5/NFA
T5 
None Transcription factor involved in the transcriptional regulation of 
osmoprotective and inflammatory  genes. Regulates hypertonicity-
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SNP CHR GENE 
(nearest/G
RAIL) 
Drugs Gene function (from; http://www.genecards.org/) 
induced cellular accumulation of osmolytes 
rs7188445 16 MAF/MAF None MAF (v-maf avian musculoaponeurotic fibrosarcoma oncogene 
homolog) is a protein-coding gene. Diseases associated with MAF 
include nephrogenic adenofibroma, and plasma cell leukemia. GO 
annotations related to this gene include sequence-specific DNA 
binding and sequence-specific DNA binding transcription factor 
activity. An important paralog of this gene is NRL. 
rs7224610 17 HLF/HLF None HLF (hepatic leukemia factor) is a protein-coding gene. Diseases 
associated with HLF include leukemia, acute lymphoblastic 3, and 
acute lymphoblastic leukemia. GO annotations related to this gene 
include double-stranded DNA binding and sequence-specific DNA 
binding transcription factor activity. An important paralog of this gene 
is DBP. 
rs742132 6 LRRC16A/L
RRC16A 
None LRRC16A (leucine rich repeat containing 16A) is a protein-coding 
gene. Diseases associated with LRRC16A include acute urate 
nephropathy. An important paralog of this gene is LRRC16B. 
rs2307394 2 ORC4L/AC
VR2A 
None/Dasatinib,Les
taurtinib,Alvocidib 
ORC4 (origin recognition complex, subunit 4) is a protein-coding 
gene. Diseases associated with ORC4 include meier-gorlin 
syndrome 2, and meier-gorlin syndrome. GO annotations related to 
this gene include DNA replication origin binding and nucleotide 
binding./ACVR2A (activin A receptor, type IIA) is a protein-coding 
gene. Diseases associated with ACVR2A include multiple 
synostoses syndrome. GO annotations related to this gene include 
PDZ domain binding and growth factor binding. An important paralog 
of this gene is ACVR1C. 
rs17786744 8 STC1/STC1 None STC1 (stanniocalcin 1) is a protein-coding gene. Diseases 
associated with STC1 include pheochromocytoma, and 
fibrosarcoma. GO annotations related to this gene include hormone 
activity. An important paralog of this gene is STC2.     The protein 
may play a role in the regulation of renal and intestinal calcium and 
phosphate transport, cell metabolism, or cellular calcium/phosphate 
homeostasis.  
rs2079742 17 BCAS3/C17
orf82 
None BCAS3 (breast carcinoma amplified sequence 3) is a protein-coding 
gene. Diseases associated with BCAS3 include breast  
cancer./C17orf82 (chromosome 17 open reading frame 82) is a 
protein-coding gene. 
rs164009 17 QRICH2/PR
PSAP1 
None QRICH2 (glutamine rich 2) is a protein-coding gene./ PRPSAP1 
(phosphoribosyl pyrophosphate synthetase-associated protein 1) is 
a protein-coding gene. GO annotations related to this gene include 
enzyme inhibitor activity and magnesium ion binding. An important 
paralog of this gene is PRPS1. 
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Table S10. Sensitivity tests with different covariate models.  
Outcome/Exposure Covariates 
Point estimate: IV (OR) 
(95% CI) from MVMR 
with specified model; 
full data. 
Mean (median) estimate 
from sensitivity test in which 
the model was fitted 
100,000 times removing 6 
SNPs at random from the 
data in each cycle. 
95% range of estimates from 
sensitivity test. 
% of estimates from 
the sensitivity test 
which lie outside the 
confidence interval of 
the IV regression. 
CHD/Urate - 1.177 (1.076, 1.286) 1.184 (1.176) 1.122, 1.299 4.85 
CHD/Urate HDL 1.094 (0.991, 1.208) 1.096 (1.094) 1.044, 1.168 0.34 
CHD/Urate TG 1.173 (1.068, 1.289) 1.18 (1.169) 1.111, 1.314 6.43* 
CHD/Urate DBP 1.097 (1, 1.202) 1.098 (1.103) 1.022, 1.166 0.92 
CHD/Urate SBP 1.121 (1.024, 1.227) 1.118 (1.128) 1.008, 1.176 2.89 
CHD/Urate SBP+HDL 1.111 (1.006, 1.227) 1.108 (1.119) 0.996, 1.171 2.77 
CHD/Urate SBP+TG 1.136 (1.033, 1.249) 1.134 (1.141) 1.031, 1.216 2.83 
CHD/Urate SBP+DBP 1.101 (1.003, 1.208) 1.101 (1.108) 1.013, 1.166 2.12 
CHD/Urate HDL+TG 1.102 (0.999, 1.217) 1.103 (1.099) 1.045, 1.195 0.75 
CHD/Urate HDL+DBP 1.09 (0.987, 1.203) 1.091 (1.095) 1.018, 1.165 1.04 
CHD/Urate TG+DBP 1.107 (1.005, 1.218) 1.107 (1.111) 1.028, 1.2 1.53 
CHD/Urate TG+DBP+HDL 1.094 (0.991, 1.208) 1.092 (1.095) 1.016, 1.18 1.34 
CHD/Urate SBP+HDL+DBP 1.095 (0.991, 1.211) 1.095 (1.101) 1.006, 1.169 2.04 
CHD/Urate SBP+TG+DBP 1.114 (1.011, 1.228) 1.112 (1.118) 1.023, 1.202 2.13 
CHD/Urate SBP+HDL+TG 1.116 (1.011, 1.232) 1.111 (1.118) 1.017, 1.19 2.42 
CHD/Urate SBP+HDL+TG+DBP 1.101 (0.996, 1.218) 1.096 (1.101) 1.013, 1.185 1.89 
CHD/Urate MR Egger method 1.049 (0.918, 1.200) 1.035 (1.045) 0.699, 1.134 3.81 
 
* Distribution of sensitivity test does not fit within the assumed normal distribution of the point estimate in full data for the model. This indicates 
that the model is sensitive to SNP selection and the confidence interval on the point estimate is anti-conservative. Conversely if the value is less 
than 5% it suggests the model is insensitive to SNP selection and the interval on the point estimate is likely to be conservative.
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Figure S1. The distribution of plasma urate concentration in the UCLEB consortium data. 
 
 
  
  
12 
 
 
Figure S2. Power curves derived from analytical outcomes. The vertical lines represent the effect, 
estimated by each method, of plasma urate concentration on CHD risk, colour coded as legend.  
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Figure S3. Observational association between plasma urate concentration and relative risk of CHD 
in 17 prospective population-based cohorts. Summary estimates obtained by fixed-effects (FE) and 
random effects (RE) meta-analysis are presented. Adjustment: + age and sex; +++ age, sex, 
smoking and some additional risk factors (not specified by original author), ++++ as +++ with 
adjustment for pre-existing CHD. Apart from UCLEB (BWHHS) the data were obtained from 
Wheeler et al. 2005,s18 the order of studies mirrors that publication.. (Size of point markers is 
proportional to the inverse variance). W = Women, M = Men. 
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Figure S4. The association of individual SNPs and the 31 SNP instrument for plasma urate 
concentration with continuous phenotypes. (Error bars are 95%CI, SNP order is by magnitude of 
effect within a phenotype, and all effects are with respect to the urate raising allele). Significant 
association in the 31 SNP instrument is indicative of pleiotropy. 
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Figure S5. The association of individual SNPs and the 31 SNP instrument for plasma urate 
concentration with continuous phenotypes. (Error bars are 95%CI, SNP order is by magnitude of 
effect within a phenotype, and all effects are with respect to the urate raising allele). Significant 
association in the 31 SNP instrument is indicative of pleiotropy. 
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Figure S6. The association of the individual SNPs and the 31 SNP instrument for plasma urate 
concentration with blood pressure. (Error bars are 95%CI, SNP order is by magnitude of effect 
within a phenotype, and all effects are with respect to the urate raising allele). Significant 
association in the 31 SNP instrument is indicative of pleiotropy. 
 
 
 
 
Figure S7. The association of the individual SNPs and the 31 SNP instrument for plasma urate 
concentration with binary phenotypes. (Error bars are 95%CI, SNP order is by magnitude of effect 
within a phenotype, and all effects are with respect to the urate raising allele). Significant 
association in the 31 SNP instrument is indicative of pleiotropy. 
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Figure S8. Funnel plot of individual IV beta estimates for SNPs in the instrument. The distribution 
about the point estimate is asymmetric suggesting there is an unmeasured net pleiotropic effect on 
the instrument. (Egger test for funnel plot symmetry P.value = 0.011). 
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Figure S9. Sensitivity tests. The assumed normal distribution (black) of the point estimate 
of the IV beta using the 31 SNP instrument with (B) and without (A) covariates. Similar for 
MR Egger regression(C). In each case the red curve is the empirical distribution of the IV 
beta estimated in 100 000  25 SNP instruments obtained by repeatedly excluding 6 SNPs 
at random.  
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Figure S10. Association of SNPs with plasma urate concentration and risk of coronary heart 
disease. Effect estimates are as figure 2 in the main paper except that in this figure all effect 
estimates have been adjusted to be relative to the urate raising allele of the SNP. This allows the 
Egger Mendelian randomisation to be represented in the same figure. Error bars are 95% CI in 
each dimension. 
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